Linerixibat Significantly Reduces Pruritus in PBC The GLISTEN trial tested the safety, efficacy, and impact of linerixibat on patients’ health-related quality of life compared with a placebo.

#Linerixibat significantly reduces #Pruritus compared with placebo in patients with #PrimaryBiliaryCholangitis (PBC), according to results from the phase 3 clinical GLISTEN trial (#NCT04950127). Published in @lancetgastrohep.bsky.social

Read here: https://bit.ly/4oZ6tKk

#RareDisease #ClinicalTrial